On Tuesday, General Motors' (NYSE: GM ) marketing VP, Chris Perry, said his company will resume buying Facebook� (NASDAQ: FB ) advertisements for the first time since last May.
The new ads -- which are part of a GM advertising "test program" -- will feature the Chevrolet Sonic, an entry-level subcompact car with which GM is targeting younger buyers given its "youthful style and driving experience."
2013 Chevrolet Sonic RS. Photo: GM.
Given the younger target audience for the vehicle, I suppose it should come as no surprise that GM is only taking advantage of Facebook's mobile ad platform for now.
So why's this a big deal?
Last time around, while GM was more than happy to keep its free Facebook page alive, the automaker made the high-profile decision to stop paying for ads on Facebook just days before the social network's much-hyped initial public offering.
Top 5 Promising Stocks For 2015: H&E Equipment Services Inc.(HEES)
H&E Equipment Services, Inc. operates as an integrated equipment services company. The company rents, sells, and provides parts and service support for hi-lift or aerial work platform equipment, crane, earthmoving equipment, and industrial lift truck categories. It offers heavy construction and industrial equipment for rent on a daily, weekly, and monthly basis. As of December 31, 2011, the company?s fleet consisted of 17,538 pieces of equipment. It also sells new heavy construction and industrial equipment in various categories. In addition, the company sells used equipment from its rental fleet, as well as inventoried equipment that is acquired through trade-ins from its customers and selective purchases; and new and used parts. Further, it provides maintenance and repair services; and ongoing preventative maintenance services and warranty repairs, as well as offers ancillary equipment support activities, including transportation, hauling, parts shipping, and loss damag e waivers. The company provides its services to industrial and commercial companies, construction contractors, manufacturers, public utilities, municipalities, and maintenance contractors, as well as for other industrial accounts. As of February 28, 2012, it operated a network of 65 full-service facilities, serving approximately 29,800 customers across 22 states in the West Coast, Intermountain, Southwest, Gulf Coast, Southeast, and Mid-Atlantic regions of the United States. The company markets its equipment rental services, and new and used equipment through its sales force. H&E Equipment Services, Inc. was founded in 1961 and is headquartered in Baton Rouge, Louisiana.
Advisors' Opinion:- [By Peter Graham]
The Q2 2014 earnings report for equipment rental stock United Rentals, Inc (NYSE: URI), a peer or competitor of Essex Rental Corp (NASDAQ: ESSX) and H&E Equipment Services, Inc (NASDAQ: HEES), is scheduled for after the market closes on Wednesday. Aside from the United Rentals earnings report, it should be said that the Essex Rental Corp reported Q4 2013 earnings on May 7th while the estimated release date for the H&E Equipment Services, Inc Q2 2014 earnings report is August 4th. However, United Rentals��shares rose after its last earnings report plus analysts have issued bullish research notes since then.
- [By Seth Jayson]
Margins matter. The more H&E Equipment Services (Nasdaq: HEES ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong H&E Equipment Services's competitive position could be.
Top 10 Industrial Disributor Stocks To Invest In 2014: Capital Senior Living Corp (CSU)
Capital Senior Living Corporation, incorporated on October 25, 1996, is an operator of residential communities for senior adults. The Company provides senior living services. Its communities integrate independent living, assisted living and home care services, to provide residents the opportunity to age in place. The Company operated 112 senior living communities in geographically concentrated regions with an aggregate capacity of approximately 14,600 residents.
The Company�� senior living options include independent living, assisted living, memory care and planning resources. The Company�� services include special nutrition counseling, additional housekeeping and laundry, exercise programs, recreation and entertainment, medication reminders and access to a choice of home health agencies.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Capital Senior Living (NYSE: CSU ) , whose recent revenue and earnings are plotted below. - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Capital Senior Living (NYSE: CSU ) , whose recent revenue and earnings are plotted below.
Top 10 Industrial Disributor Stocks To Invest In 2014: Marketo Inc (MKTO)
Marketo, Inc. (Marketo), incorporated on December 17, 2009, provides cloud-based marketing software platform that enables organizations to engage in modern relationship marketing. The Company�� software platform is designed to enable the execution, management and analytical measurement of marketing activities, helping organizations to acquire new customers. The Company�� platform includes marketing automation, social marketing, sales insight and revenue analytics. Its customer base includes 2,000 customers across a range of industries, including business services, consumer, financial services, healthcare, manufacturing, media, technology and telecommunications. The Company provides its solutions on a subscription basis. Effective December 19, 2013, Marketo Inc acquired Insightera Ltd.
The Company designs, builds and markets a suite of integrated applications to address the needs of modern marketing professionals. The Company�� customers use these applications individually and in combination to streamline and automate marketing processes; develop, retain and extend customer relationships, and measure the positive impact on revenue of marketing programs. Its platform and suite of applications is hosted and delivered over the Web using a cloud-based, or software as a service (SaaS) model, and is built using a multi-tenant architecture. The Company markets and sells its enterprise applications as: Marketo lead management, which includes the core Marketo platform, plus all of the marketing automation capabilities available on the platform; Marketo social marketing, which enables social media campaigns, such as referrals, sweepstakes, and other customer engagement campaigns, and also includes features to add social marketing extensions to traditional marketing campaigns; Marketo sales insight, which provides insights to salespeople about their customers and prospects, and Marketo revenue cycle analytics, which is a suite of analytic tools, analyzers, and ad hoc reporting capabilities taki! ng advantage of its time-series analytics engine.
The Company has built a suite of applications that run on its platform. The applications include marketing automation, social marketing, sales insight and revenue analytics. Marketing automation provides a set of capabilities for marketers to create, automate, and track personalized multi-channel marketing campaigns and relationship-marketing workflows. It includes functionality for marketers to finely segment their prospect and customer database based on collected demographic and behavioral data; generate custom Web pages without programming; send batch and individual personalized marketing messages over email, short message service (SMS) text, and other channels; streamline the entire process of running online (e.g., webinar) and offline (e.g., trade show) marketing events, and to execute multi-step lead nurturing and relationship-marketing campaigns that can run over days, weeks, or months.
Social marketing enables marketers to run social media marketing campaigns, as well as to an increase traditional marketing campaigns with a social marketing aspect in order to amplify marketing messages across social networks. Its solution lets marketers add intelligent social sharing buttons to existing Web content and videos; publish new Facebook pages with the touch of a button; build social engagement applications, such as polls, sweepstakes, and referral offers to engage their audience and promote social cross-posting, and increase existing customer and prospect information with social profiles and sharing behavior.
Sold on a per-seat basis, the Company offers sales insight application to customers utilizing Microsoft dynamics customer relationship management (CRM) or salesforce.com as their CRM system. Revenue Analytics provides a range of ways to help companies understand the correlation between marketing programs and revenue outcomes, and includes: a library of operational reports detailing e-mail and landing page per! formance,! Web activity, and lead performance; intuitive analyzers that show the influence of marketing on individual customer outcomes; analytics that compute and illustrate the impact, effectiveness and return on investment of marketing programs individually and in aggregate, and an ad-hoc report builder for completely customized reports and dashboards.
The Company competes with Act-On, Eloqua, Aprimo, HubSpot, SAS Institute, Unica, ExactTarget, Responsys, Silverpop, Oracle Corporation and SAP AG.
Advisors' Opinion:- [By Evan Niu, CFA]
What: Shares of Marketo (NASDAQ: MKTO ) have dropped like a rock today, down by as much as 12% following an analyst downgrade.
So what: UBS dropped its rating on the marketing software maker from "neutral" to "sell," while keeping its $22 price target unchanged. The firm is concerned about Marketo's valuation, since shares have nearly doubled in less than two months since going public at $13.
- [By Jon C. Ogg]
Marketo Inc. (NASDAQ: MKTO) was reinstated as Outperform with a $38 price target (versus a $31.49 close) at Credit Suisse.
Nike Inc. (NYSE: NKE) was started as Neutral at UBS.
Top 10 Industrial Disributor Stocks To Invest In 2014: Tranzyme Inc.(TZYM)
Tranzyme, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of acute and chronic gastrointestinal (GI) motility disorders in the United States and internationally. The company?s clinical product candidates include ulimorelin, an intraveneous ghrelin agonist, which is in the Phase III clinical development stage for the treatment of acute upper GI motility disorders; and TZP-102, an orally-administered ghrelin agonist that has commenced Phase IIb clinical development stage for the treatment of diabetic gastroparesis. Its preclinical product candidates comprise TZP-201, a motilin antagonist for the treatment of various forms of moderate-to-severe diarrhea; and TZP-301, an oral ghrelin antagonist for the treatment of metabolic diseases. The company has strategic collaboration with Bristol-Myers Squibb Company to discover, develop, and commercialize additional novel co mpounds; and a license agreement with Norgine B.V to develop and commercialize ulimorelin in Europe, Australia, New Zealand, the Middle East, and north and South Africa. Tranzyme, Inc. was founded in 1998 and is headquartered in Durham, North Carolina.
Advisors' Opinion:- [By CRWE]
Tranzyme Pharma (Nasdaq:TZYM) reported that it has closed the previously announced underwritten registered direct offering of approximately 3.0 million shares of its common stock at a price of $3.85 per share for gross proceeds, including the over-allotment option, of approximately $11.5 million.
Top 10 Industrial Disributor Stocks To Invest In 2014: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By Sean Williams]
Cell Therapeutics (NASDAQ: CTIC )
Certainly no discussion of companies with large accumulated deficits would be complete without discussing a biotechnology company. It's perfectly understandable to see a biotech, especially a clinical-stage one, run with an accumulated deficit, as it takes time and money to build up a drug pipeline. However, after multiple complete response letters (the equivalent of a rejection) by the Food and Drug Administration and years without an approved drug, Cell Therapeutics racked up an astounding $1.83 billion in accumulated deficits through the end of fiscal 2012. By comparison, that's nearly 56 times larger than its shareholder equity.� - [By John Udovich]
If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:
- [By Bryan Murphy]
Like it or not, all good things must come to an end.... even for a red hot stock like Cell Therapeutics Inc. (NASDAQ:CTIC). Yes, CTIC is up 111% since the end of 2013, up 14% today alone, and it doesn't look like the bulls have any reason to slow down now. That's exactly why now's the time for current shareholders to be afraid, however - expect it when you least expect it.
- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
Top 10 Industrial Disributor Stocks To Invest In 2014: Fortegra Financial Corporation (FRF)
Fortegra Financial Corporation, an insurance services company, provides distribution and administration services primarily in the United States. The company�s Payment Protection segment delivers credit insurance, debt protection, warranty and service contracts, and motor club solutions under the Life of the South, Continental Car Club, United Motor Club, and Auto Knight Motor Club brand names to consumer finance companies, regional banks, community banks, retailers, small loan companies, warranty administrators, automobile dealers, vacation ownership developers, and credit unions. This segment specializes in providing products that protect consumer lenders and their borrowers from death, disability, or other events that could impair their borrowers' ability to repay a debt. Fortegra Financial Corporation�s Business Process Outsourcing segment offers various administrative services under the Consecta and Pacific Benefits Group Northwest, LLC brand names to insurance and o ther financial services companies. This segment�s services include sales and marketing, electronic underwriting, premium billing and collections, policy administration, claims adjudication, and call center management services. The company�s Brokerage segment sells specialty property and casualty, and surplus lines insurance to retail insurance brokers and agents, and insurance companies under the Bliss & Glennon, eReinsure.com, Inc., and South Bay Acceptance Corporation brand names. This segment also provides its clients the ability to obtain various types of commercial insurance coverage outside of their core areas of focus. In addition, it offers insurance underwriting services as a managing general agent for specialized insurance carriers. The company was formerly known as Life of the South Corporation and changed its name to Fortegra Financial Corporation in 2008. The company was incorporated in 1981 and is based in Jacksonville, Florida.
Advisors' Opinion:- [By Hilary Kramer]
I am a big fan of financials, which is why I named Fortegra Financial (FRF) as the best stock of 2014. Fortegra isn�� your traditional bank or financial company, but it has great potential.
Top 10 Industrial Disributor Stocks To Invest In 2014: Verso Paper Corp.(VRS)
Verso Paper Corp. engages in the production and sale of coated papers in the United States. The company offers coated groundwood paper, which is used primarily for catalogs and magazines; coated freesheet paper that is used primarily for annual reports, brochures, and magazine covers; and supercalendered paper, which is primarily used for retail inserts. It also provides northern bleached hardwood kraft pulp that is used to manufacture printing and writing paper grades, and tissue products; recycled paper to meet specific customer requirements; and customized product solutions by producing paper grades with customer-specified weight, brightness, and pulp mix characteristics. In addition, the company offers ultra-lightweight uncoated printing papers, and ultra-lightweight coated and uncoated flexible packaging papers. It serves catalog, magazine, insert, and commercial printing markets through direct sales, commercial printers, paper merchants, and brokers. The company was founded in 2006 and is headquartered in Memphis, Tennessee.
Advisors' Opinion:- [By John Udovich]
Small cap�paper stock�Verso Paper Corp (NYSE: VRS), trucking stock�Covenant Transportation Group, Inc (NASDAQ: CVTI) and gold mining stock Richmont Mines Inc (NYSEMKT: RIC) are among the best small cap stock performers for the�year and the best in their respective sectors because they are�up 390.7%, 224.7% and 215%, respectively, since the start of the year. Why has the paper, trucking and gold mining sector produced three top performing small cap stocks? Here are some answers:
No comments:
Post a Comment